According to a recent LinkedIn post from JenaValve Technology Inc, the company is promoting a breakfast symposium focused on aortic regurgitation at the Heart Valve Society 2026 meeting. The session is scheduled for April 17 in the Grand Ballroom and will feature experts in imaging, surgery, and transcatheter aortic valve replacement.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post highlights discussion topics including patient populations, surgical decision-making, and the emerging role of transcatheter options across the spectrum of aortic regurgitation care. For investors, this outreach suggests an effort to strengthen clinical engagement and visibility in the structural heart and TAVR market, which could support long-term adoption of the company’s technologies if they align with evolving treatment practices.